Brodiak I V, Sybirna N O
Ukr Biokhim Zh (1999). 2006 Sep-Oct;78(5):114-9.
It was shown that administration of aminoguanidine is accompanied by a decrease of the content of nitric oxide stable metabolites, as well as protein carbonyl groups in leukocytes and blood plasma in diabetic and control animals. Aminoguanidine is proposed to be used for pharmacological correction of NO biosynthesis. Aminoguanidine, being the selective iNOS inhibitor, antioxidant and the factor eliminating post-translational protein nitrozylation and oxidative modification, weaken the toxic effects of NO and positively modulates the pathological state caused by NO hyperproduction.
结果表明，在糖尿病动物和对照动物中，给予氨基胍会伴随着一氧化氮稳定代谢产物的含量降低，以及白细胞和血浆中蛋白质羰基基团的含量降低。氨基胍被提议用于一氧化氮生物合成的药理校正。氨基胍作为选择性诱导型一氧化氮合酶抑制剂、抗氧化剂以及消除翻译后蛋白质亚硝基化和氧化修饰的因子，可减弱一氧化氮的毒性作用，并对一氧化氮过度产生所导致的病理状态产生正向调节作用。
